BACKGROUND: The primary endpoint was to improve local tumour control of patients with metastatic spinal tumours by stereotactic body radiotherapy (SBRT) and dose escalation by simultaneous, integrated boost (PTV-boost). We used a whole vertebral body (PTV-elective) contouring approach. Secondary endpoints were severity of acute and chronic adverse effects and overall survival. METHODS: In all, 33 patients with metastases of the vertebral column were treated at Erlangen University Hospital. SBRT was given in 12 or 10 fractions. The metastatic lesion (PTV-boost) received 3.6 Gy (range 3.0-4.51 Gy) per fraction for a total of 42.0 Gy (24.36-48.0 Gy) and the whole vertebra (PTV-elective) received 2.85 Gy (range 1.8-3.6 Gy) per fraction for a total of 32.39 Gy (range 21.60-38.0 Gy). Patients were followed up every 3 months. RESULTS: Local control rate of all patients was 93% at 12 and 24 months. The overall survival rate was 54% at 12 months, 38% at 24 months and 18% at 36 months. No radiation myelopathy occurred. The most frequently observed adverse events in 3 cases was oesophagitis grade 2. CONCLUSION: SBRT with simultaneous, integrated boost was associated with excellent local control of 93% after 24 months. This result shows the possibility of delivering escalated doses to the target while still keeping the incidence of side effects low. This study forms the basis for a future randomised controlled trial comparing conventional radiotherapy (10 fractions of 3 Gy) with hypofractionated dose intensified SBRT (12 fractions of 3 Gy + integrated boost 12 fractions of 4 Gy) for improvement of local tumour control and pain.
BACKGROUND: The primary endpoint was to improve local tumour control of patients with metastatic spinal tumours by stereotactic body radiotherapy (SBRT) and dose escalation by simultaneous, integrated boost (PTV-boost). We used a whole vertebral body (PTV-elective) contouring approach. Secondary endpoints were severity of acute and chronic adverse effects and overall survival. METHODS: In all, 33 patients with metastases of the vertebral column were treated at Erlangen University Hospital. SBRT was given in 12 or 10 fractions. The metastatic lesion (PTV-boost) received 3.6 Gy (range 3.0-4.51 Gy) per fraction for a total of 42.0 Gy (24.36-48.0 Gy) and the whole vertebra (PTV-elective) received 2.85 Gy (range 1.8-3.6 Gy) per fraction for a total of 32.39 Gy (range 21.60-38.0 Gy). Patients were followed up every 3 months. RESULTS: Local control rate of all patients was 93% at 12 and 24 months. The overall survival rate was 54% at 12 months, 38% at 24 months and 18% at 36 months. No radiation myelopathy occurred. The most frequently observed adverse events in 3 cases was oesophagitis grade 2. CONCLUSION: SBRT with simultaneous, integrated boost was associated with excellent local control of 93% after 24 months. This result shows the possibility of delivering escalated doses to the target while still keeping the incidence of side effects low. This study forms the basis for a future randomised controlled trial comparing conventional radiotherapy (10 fractions of 3 Gy) with hypofractionated dose intensified SBRT (12 fractions of 3 Gy + integrated boost 12 fractions of 4 Gy) for improvement of local tumour control and pain.
Authors: Arjun Sahgal; Mark Bilsky; Eric L Chang; Lijun Ma; Yoshiya Yamada; Laurence D Rhines; Daniel Létourneau; Matthew Foote; Eugene Yu; David A Larson; Michael G Fehlings Journal: J Neurosurg Spine Date: 2010-12-24
Authors: Dirk Rades; Lukas J A Stalpers; Theo Veninga; Rainer Schulte; Peter J Hoskin; Nermina Obralic; Amira Bajrovic; Volker Rudat; Rudolf Schwarz; Maarten C Hulshof; Philip Poortmans; Steven E Schild Journal: J Clin Oncol Date: 2005-05-20 Impact factor: 44.544
Authors: Arjun Sahgal; Vivian Weinberg; Lijun Ma; Eric Chang; Sam Chao; Alexander Muacevic; Alessandra Gorgulho; Scott Soltys; Peter C Gerszten; Sam Ryu; Lilyana Angelov; Iris Gibbs; C Shun Wong; David A Larson Journal: Int J Radiat Oncol Biol Phys Date: 2012-06-17 Impact factor: 7.038
Authors: Frederick Mantel; Stefan Glatz; André Toussaint; Michael Flentje; Matthias Guckenberger Journal: Strahlenther Onkol Date: 2014-06-27 Impact factor: 3.621
Authors: Arjun Sahgal; Lijun Ma; Iris Gibbs; Peter C Gerszten; Sam Ryu; Scott Soltys; Vivian Weinberg; Shun Wong; Eric Chang; Jack Fowler; David A Larson Journal: Int J Radiat Oncol Biol Phys Date: 2009-09-16 Impact factor: 7.038
Authors: Ingmar Schlampp; Stefan Rieken; Daniel Habermehl; Thomas Bruckner; Robert Förster; Jürgen Debus; Harald Rief Journal: Strahlenther Onkol Date: 2014-04-01 Impact factor: 3.621
Authors: Tanja Sprave; Stefan Ezechiel Welte; Thomas Bruckner; Robert Förster; Tilman Bostel; Ingmar Schlampp; Nils Henrik Nicolay; Jürgen Debus; Harald Rief Journal: Trials Date: 2018-01-22 Impact factor: 2.279
Authors: Markus Hecht; Friedegund Meier; Lisa Zimmer; Bülent Polat; Carmen Loquai; Carsten Weishaupt; Andrea Forschner; Ralf Gutzmer; Jochen S Utikal; Simone M Goldinger; Michael Geier; Jessica C Hassel; Panagiotis Balermpas; Felix Kiecker; Ricarda Rauschenberg; Ursula Dietrich; Patrick Clemens; Carola Berking; Gerhard Grabenbauer; Dirk Schadendorf; Stephan Grabbe; Gerold Schuler; Rainer Fietkau; Luitpold V Distel; Lucie Heinzerling Journal: Br J Cancer Date: 2018-02-13 Impact factor: 7.640
Authors: Alexander Rühle; Verlaine Ange Nya Yompang; Simon K B Spohn; Raluca Stoian; Constantinos Zamboglou; Eleni Gkika; Anca-Ligia Grosu; Nils H Nicolay; Tanja Sprave Journal: Radiat Oncol Date: 2022-09-07 Impact factor: 4.309